Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be measured. Information about any side effects that may occur will also be collected.
Participants will be on study for 21 days with a follow-up at least 7 days afterwards.
Screening will be undertaken within 45 days prior to enrollment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Women not of childbearing potential may participate and include those who are:
Caucasian and may be of Hispanic ethnicity
Body mass index (BMI) of 19 to 32 kilogram per meter square (kg/m²), inclusive, at the time of screening
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
42 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal